header logo image


Page 1,021«..1020..1,0201,0211,0221,023..1,0301,040..»

Plandai Biotechnology Names Ezra Jones as Vice President of Sales and Marketing – Yahoo Finance

April 28th, 2017 3:41 pm

LONDON, UNITED KINGDOM--(Marketwired - Apr 28, 2017) - Planda Biotechnology, Inc. ( OTC PINK : PLPL ) ("Planda" or "the Company"), producer of the highly bioavailable Phytofare catechin complex, today announced that Ezra Jones has been appointed Vice President of Sales and Marketing, a role he assumes from Callum Cottrell-Duffield, who was recently named Chief Operating Officer of Planda.

Mr. Jones has been involved in sales of nutraceutical branded ingredients for the past 18 years. He was he was with NutraGenesis for 3.5 years, and has recently, before Planda, been working as an independent sales representative for numerous worldwide companies.Since 2016, Mr. Jones has overseen all North American sales efforts for Planda.As the new head of sales and marketing, his responsibilities will expand to overseeing all global sales efforts, working with the company's independent sales reps and distributors, building additional sales channels, and growing the Phytofare brand.

Callum Cottrell-Duffield, President of Planda, commented, "Having worked with Ezra for the past year, I have been impressed with his passion for the product and knowledge of the industry.He has been instrumental in opening our largest accounts and is a driven salesman.As we now expand into a global brand and introduce new products in the coming year, Ezra's experience in building and training a sales force will be invaluable."

About Planda Biotechnology, Inc.

Planda Biotechnology, Inc. and its subsidiaries develop highly phyto-available extracts. Planda Biotechnology controls every aspect of the process, from growing green tea on its farms in South Africa, to producing its proprietary Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.

Read more here:
Plandai Biotechnology Names Ezra Jones as Vice President of Sales and Marketing - Yahoo Finance

Read More...

Improving Joint Health with Putative Therapeutics at Matis, Iceland’s … – SelectScience

April 28th, 2017 3:41 pm

Use of cell imaging technology enables cutting-edge research into the assessment of bioactive compounds in cell lines

Matis is a leading food and biotechnology research institute in Iceland. Matis vision is to increase the value of food processing and food production, and to ensure the safety and quality of food and food products. SelectScience spoke to Dr. Eva Kuttner, to learn more about the technology the company is using in its research.

SS: Could you briefly introduce yourself and your place of work?

EK: My name is Dr. Eva Kuttner, Im a Project Leader in the Analysis and Structure division at Matis (mat=food + is=Iceland). Matis is a government owned, non-profit, independent research company in Iceland. The main focus of Matis is research and development, aligned to the food and biotechnology industries, as well as providing Iceland's leading food analytical testing service for public and private authorities.

I personally am German, and I hold a Diploma (equal to an MSc) in Botany, from the Universitt Braunschweig in Germany. I received my PhD in Integrative Biology (2007-2012) from the University of Guelph (Ontario, Canada).

SS: Could you describe your job role and work at Matis?

EK: My job title is Regional Manager, which means I am responsible for the 2 locations of Matis in the North of Iceland, Saurkrkur and Akureyri. My main work is that of a project leader (bioactives) in the Analysis and Structure Division and I am specialized in screening for bioactive secondary metabolites using in vitro chemical and cell-based assays.

Our laboratory focus is on identifying and describing compounds regarding antioxidant activity for healthcare (anti-diabetes, anti-inflammatory) and skin care. We now have a fully equipped cell laboratory (currently working with two cell lines), and we routinely run chemical and cell-based assays to identify and describe the bioactivity properties of extracted and fractionated compounds.

Testing putative therapeutics

SS: Please tell us about your marine compounds project that you are working on, and the main challenges involved?

EK: We are currently looking into how marine compounds influence the mineralization in a murine chondrocyte cell line (ATDC5). The aim of the project is to test putative therapeutics, to improve joint health. Specifically, we are interested in seeing how they affect differentiation of these cells.

SS: Which methods do you use to investigate this project and how does the BioTek Cytation 5 play a part in this?

EK: We are exposing the cells to different concentrations of fractionated marine compounds in a 96-well microplate format. After 24 days of incubation we stain the cells both with calcein and Alizarin Red to quantify calcium deposition. This is when the Cytation 5 from BioTek comes in: we have a workflow set up that images (magnification 4x) each well in phase contrast and fluorescence (we are using a GFP filter cube for this assay), and also carries out a read of the fluorescence signal. We then perform the Alizarin Red staining, take more pictures and extract the bound color after several washing steps. A further reading step quantifies the Alizarin Red using an absorbance read.

The figure below shows an example read of the calcein stain: first picture, phase contrast, second picture, fluorescence channel (GFP filter cube) and the third picture, overlay of both:

Image courtesy of Dr. Eva Kuttner

SS: What are your main research findings so far?

EK: We have identified several possible inhibitors of mineralization, but we are still in the process of improving the assay protocol to make the quantification of the mineralization more reproducible. The Alizarin Red stain has proven to represent more accurate calcium deposition into the cells, when testing the assay protocol using standard inhibitors like levamisole, so we are using the calcein stain to visualize mineralization, and Alizarin Red to quantify.

SS: What is the future of your research?

EK: We are looking into setting up assays investigating blood pressure. Our project partner developed a product line based on fish protein hydrolysate using trimmings from cod (Gadus morhua). The proteins are extracted and broken down to smaller peptides that have been shown to inhibit a key enzyme involved in increasing blood pressure (ACE). For this research we will develop and perform cell-based assays.

Read more:
Improving Joint Health with Putative Therapeutics at Matis, Iceland's ... - SelectScience

Read More...

iShares NASDAQ Biotechnology Index (IBB) Upgraded to Buy at … – The Cerbat Gem

April 28th, 2017 3:41 pm

More:
iShares NASDAQ Biotechnology Index (IBB) Upgraded to Buy at ... - The Cerbat Gem

Read More...

Stem cells edited to fight arthritis: Goal is vaccine that targets … – Science Daily

April 28th, 2017 3:41 pm
Stem cells edited to fight arthritis: Goal is vaccine that targets ...
Science Daily
Using CRISPR technology, a team of researchers rewired stem cells' genetic circuits to produce an anti-inflammatory arthritis drug when the cells encounter ...

and more »

Read the original post:
Stem cells edited to fight arthritis: Goal is vaccine that targets ... - Science Daily

Read More...

CRISPR-SMART Cells Regenerate Cartilage, Secrete Anti-Arthritis Drug – Genetic Engineering & Biotechnology News

April 28th, 2017 3:41 pm

We have anti-arthritis drugs. What we lack is the ability to deploy them when and where they are needed in the body. The drugs would be far more effective, and occasion fewer side effects, if they were to appear only in response to inflammation, and only in the joints. If the drugs could be delivered so painstakinglyso smartlythey wouldnt have to be administered systemically.

Although conventional drug delivery systems may be unable to respond to arthritic flares with such adroitness, cells may have better luckif they are suitably modified. Stem cells, for example, have been rewired by means of gene-editing technology to fight arthritis. These stem cells, known as SMART cells (Stem cells Modified for Autonomous Regenerative Therapy), develop into cartilage cells that produce a biologic anti-inflammatory drug. Ideally, the new cartilage cells will replace arthritic cartilage, and the biologic will protect against chronic inflammation, preserving joints and other tissues.

SMART cells of this sort were prepared by scientists based at Washington University School of Medicine in St. Louis. The scientists initially worked with skin cells taken from the tails of mice and converted those cells into stem cells. Then, using the gene-editing tool CRISPR in cells grown in culture, they removed a key gene in the inflammatory process and replaced it with a gene that releases a biologic drug that combats inflammation.

Details of this work appeared April 27 in the journal Stem Cell Reports, in an article entitled Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs. The article describes how modified stem cells grew into cartilage and produced cartilage tissue. The engineered cartilage, the scientists reported, was protected from inflammation.

Using the CRISPR/Cas9 genome-engineering system, we created stem cells that antagonize IL-1- [interleukin-1] or TNF-- [tumor necrosis factor-] mediated inflammation in an autoregulated, feedback-controlled manner, wrote the authors of the Stem Cell Reports article. Our results show that genome engineering can be used successfully to rewire endogenous cell circuits to allow for prescribed input/output relationships between inflammatory mediators and their antagonists, providing a foundation for cell-based drug delivery or cell-based vaccines via a rapidly responsive, autoregulated system.

Many current drugs used to treat arthritisincluding Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab)attack TNF-, an inflammation-promoting molecule. But the problem with these drugs is that they are given systemically rather than targeted to joints. As a result, they interfere with the immune system throughout the body and can make patients susceptible to side effects such as infections.

"We want to use our gene-editing technology as a way to deliver targeted therapy in response to localized inflammation in a joint, as opposed to current drug therapies that can interfere with the inflammatory response through the entire body," said Farshid Guilak, Ph.D., the paper's senior author and a professor of orthopedic surgery at Washington University School of Medicine. "If this strategy proves to be successful, the engineered cells only would block inflammation when inflammatory signals are released, such as during an arthritic flare in that joint."

Dr. Guilak's team encoded the stem/cartilage cells with genes that made the cells light up when responding to inflammation, so the scientists easily could determine when the cells were responding. Recently, the team began testing the engineered stem cells in mouse models of rheumatoid arthritis and other inflammatory diseases.

If the work can be replicated in animals and then developed into a clinical therapy, the engineered cells or cartilage grown from stem cells would respond to inflammation by releasing a biologic drugthe TNF- inhibitorthat would protect the synthetic cartilage cells that Dr. Guilak's team created and the natural cartilage cells in specific joints.

"When these cells see TNF-, they rapidly activate a therapy that reduces inflammation," Dr. Guilak explained. "We believe this strategy also may work for other systems that depend on a feedback loop. In diabetes, for example, it's possible we could make stem cells that would sense glucose and turn on insulin in response. We are using pluripotent stem cells, so we can make them into any cell type, and with CRISPR, we can remove or insert genes that have the potential to treat many types of disorders."

View post:
CRISPR-SMART Cells Regenerate Cartilage, Secrete Anti-Arthritis Drug - Genetic Engineering & Biotechnology News

Read More...

SMART cells open door to arthritis vaccine – New Atlas

April 28th, 2017 3:41 pm

An artist's impression of the reengineered cell that produces an anti-inflammatory drug when it encounters inflammation (Credit: Ella Marushchenko)

Combining two cellular-editing processes, researchers have developed cartilage that fights inflammation. The scientists hope that the breakthrough could eventually lead to localized injections that combat arthritis or perhaps a vaccine that would eliminate the condition altogether.

Like many of the biology breakthroughs happening today, the WU researchers started with stem cells. To be more accurate, they actually started with skin cells from the tails of mice and converted them into stem cells. They then used a gene-editing technique called CRISPR to remove a gene involved in inflammation and replace it with one that releases an anti-inflammatory drug. The resulting cells are known as SMART cells, which stands for Stem cells Modified for Autonomous Regenerative Therapy.

More than 700 New Atlas Plus subscribers read our newsletter and website without ads.

Join them for just US$19 a year.

"Our goal is to package the rewired stem cells as a vaccine for arthritis, which would deliver an anti-inflammatory drug to an arthritic joint but only when it is needed," said Farshid Guilak, the senior author of a paper about the work and a professor of orthopedic surgery at Washington University School of Medicine. "To do this, we needed to create a 'smart' cell."

As part of the current fight against arthritis, there are several drugs that work to eliminate an inflammatory molecule called tumor necrosis factor-alpha (TNF-alpha). The issue with such drugs, however, is that they work throughout the entire body, rather than only at the site of inflammation, and can have an impact on the body's overall immune system.

To change this dynamic, the researchers replaced the gene that expresses TNF-alpha with one that inhibits it by releasing a drug, basically converting the cells from those that create inflammation to those that fight it. "We hijacked an inflammatory pathway to create cells that produced a protective drug," said Jonathan Brunger, a postdoctoral fellow in cellular and molecular pharmacology at the University of California, San Francisco. They then coaxed these cells to grow into cartilage in the lab which, they found, was successful in combating inflammation.

The hope is that injecting the cells into areas afflicted by arthritis, the new anti-inflammatory cartilage could replace the old cartilage. This would effectively create a vaccine against the condition, as the newly engineered cells would only release the anti-inflammatory drug when inflammation is present such as during an arthritic flare-up and turn off the release of the drug when the flare subsides.

Additionally, the researchers also engineered the new cells to light up when they responded to inflammation so that they could track their response in the body. The cells are now being tested in mice with rheumatoid arthritis and other inflammatory disorders and the researchers think that the method of combining stem cells with CRISPR could help fight other diseases as well.

"We believe this strategy also may work for other systems that depend on a feedback loop," said Guilak. "In diabetes, for example, it's possible we could make stem cells that would sense glucose and turn on insulin in response. We are using pluripotent stem cells, so we can make them into any cell type, and with CRISPR, we can remove or insert genes that have the potential to treat many types of disorders."

The paper is published in the journal Stem Cell Reports.

Go here to read the rest:
SMART cells open door to arthritis vaccine - New Atlas

Read More...

Helping juvenile idiopathic arthritis sufferers — ScienceDaily – Science Daily

April 28th, 2017 3:41 pm

Express.co.uk
Helping juvenile idiopathic arthritis sufferers -- ScienceDaily
Science Daily
A drug combination that could help thousands of children with arthritis has been discovered by a team of researchers. Children and adolescents with Juvenile ...
Arthritis news: Condition can cause BLINDNESS in sufferers | Health ...Express.co.uk

all 5 news articles »

See the original post here:
Helping juvenile idiopathic arthritis sufferers -- ScienceDaily - Science Daily

Read More...

All About Arthritis – mySteinbach.ca (blog)

April 28th, 2017 3:41 pm

The word arthritis literally means inflammation of the joints. Joints in the body occur where bones meet. Bone ends are covered by cartilage and are encased in a fluid-filled synovial membrane used to lubricate the joint. Common symptoms are generally pain, swelling, stiffness and reduced function/mobility. However, the root causes are not always the same. There are distinctive differences between Osteo Arthritis (OA: wear & tear/degenerative joint disease) and Rheumatoid Arthritis (RA: auto-immune/inflammatory disease). Lets explore.

Who

OA: Affects both men and women. Process can begin after the age of 40 and symptoms are often present by age of 65.

RA: More common in women and can affect anyone, at any age.

When & How

OA: Gradual onset & increase in severity. Characterized by deterioration of and decreased ability to turn over (replace) cartilage tissue. This can be due to altered enzyme activity, building block deficiency and repetitive use/damage. This results in painful friction of exposed joints rubbing together, leading to inflammation of joint lining. After much cartilage is worn away, bone spurs may develop in joint spaces.

RA: Rapid onset. Characterized by an auto-immune response that leads to a self-attack on synovial membrane, which in turn leads to its inflammation, thickening, cartilage destruction and scar tissue formation.

Number & Types of Joins Affected

OA: 1-2 joints, Asymmetrical (Not even on both sides usually one side acts up first). Affects the weight-bearing joints (i.e. knees & hips).

RA: Multiple joints, Symmetrical (Affects both sides of the body the same way). Affects the synovial joints (i.e. hands & feet) but can progress to larger joints.

Non-Joint Involvement

OA: Absent.

RA: Commonly affects other tissues throughout the body. Other symptoms include fever, depression, fatigue, etc.

Types & Causes

OA: 2 Types Primary & Secondary.

Primary Potential causes include age, obesity, high impact sports, excessive use/exercise, free radical damage, poor nutrition, dehydration.

Secondary Results from a pre-disposing factor/condition such as joint or ligament damage/abnormality, infection, previous inflammation, loss of blood supply.

RA: Single Type.

Auto-immune response (when your body breaks itself down/attacks its own tissues). Potential underlying causes include poor digestion/diet (nutrition deficiencies, imbalance of gut bacteria, leaky gut, and food sensitivities), stress, chronic inflammation, heredity/genetics, imbalanced immune system, smoking/toxins and infections or overgrowth (i.e. candida).

Did you know 56% of patients with inflammatory arthritis have an imbalance of gut bacteria?

Suggestions?

1. Symptom Relief:

2. Tissue Protection: Look for Antioxidants (Quercetin, Zinc, Pycnogenol, Selenium, Vitamin E, Grape Seed Extract)

3. Repair Nutrients:

4. Topical Ingredients: Capsaicin, MSM, Arnica, Celadrin, Menthol, Peppermint, Eucalyptus.

5. Diet Tips: Avoid nightshades (i.e. tomatoes, white potatoes, eggplant, peppers and paprika), citrus, red meat, dairy, sugar, tobacco and any potential food sensitivities as they may aggravate pain & inflammation. Drink plenty of water. Eat mineral-rich and green foods to detox & alkalize. Eat more sulfur-containing foods such as garlic, onions, asparagus, etc.

6. Lifestyle Suggestions: Attain a healthy weight, manage stress and blood sugars, do light, non-weight bearing exercises (i.e. swimming). Consider wearing Cirulating Clothing!

7. Improve Gut Health: Ensure daily Probiotics and consider supplemental L-Glutamine, Enzymes/HCL, Fibre & VITAMIN D3.

8. Modulate Immunity: Consider ingredients such as Plant Sterols, Medicinal Mushrooms or Saccharomyces Cerevisiae

9. Fight Infection (if necessary): Oregano, Silver, Garlic, Grapefruit Seed Extract

Go here to read the rest:
All About Arthritis - mySteinbach.ca (blog)

Read More...

Arthritis Foundation’s Coast Classic Bike Tour Changes Course – Aptos Times

April 28th, 2017 3:41 pm

Landslide, Bridge Closure in Big Sur Result in Modified Route

LOS ANGELES Following lengthy review, organizers of the Arthritis Foundation California Coast Classic (CCC) Bike Tour presented by Amgen have announced a route change. This years 8-day flagship fundraising ride from San Francisco to Los Angeles takes place Sept. 9-16 and registration is currently open.

The new routing is for days 3 and 4, and is a bypass around the Pfeiffer Canyon Bridge on Highway 1 in Big Sur, which became structurally unstable after heavy storms caused a landslide last winter. The California Transportation Department (CalTrans) tore down the bridge in March and is building a replacement slated for completion in Sept. 2017.

While wed prefer to keep our traditional route, said Shannon Marang Cox, ride director for the CCC Bike Tour, our main priorities are rider safety and preserving the essence of the CCC riding experience. Chances are very slim that the bridge will be ready by early September, so weve decided to plan on our alternate course through Carmel Valley. The route is incredible, offering views of rivers, pastures, vineyards and mountains. Next year, well return to our original course, so this is a once-in-a-lifetime year to ride CCC.

In true Arthritis Foundation spirit, we explored many options and are forging ahead with a plan, Marang Cox continued. Weve consulted with our route team, taken several scouting trips, and kept in regular contact with CalTrans to find out whether or not the bridge will be done in time. In order to plan properly, we have to make the call now.

Days 1 and 2 of the 2017 California Coast Classic remain unchanged, as riders depart from Pier 39 in San Francisco and travel along the Pacific coast to Santa Cruz, then Monterey. On Day 3, cyclists will ride the famed 17-Mile Drive, and

then head southeast to new territory, pedaling through the bucolic Carmel Valley, alongside the Salinas River and trees draped in Spanish moss. The ride will stop for an overnight in King City.

The Day 4 route traverses the rolling Santa Lucia Mountain foothills and takes riders on a spin between Lake San Antonio and Lake Nacimiento on the way to their overnight stop in Paso Robles, which is known for hot springs and world-class wineries. On Day 5, the riders rejoin the original CCC route into Oceano, continuing to Buellton, and Ventura, and arriving in Los Angeles on Saturday, Sept. 16.

In developing our alternate route, we selected roads that provide the exceptional rider experience that CCC is known for, said Eli Campbell, CEO of Sentio Cycling, which provides logistics assistance to CCC. The bypass adds about 45 miles and an additional 2,700 of elevation gain, pending final permitting. Our 2017 route will rival previous years and offer a top-notch and rewarding experience for all.

Registration for the California Coast Classic, named one of The 30 Best Road Biking Trips by Outside Magazine, is capped at 250 riders and expected to sell out again in 2017. The eight-day, full-service, fully supported ride from San Francisco to Los Angeles raises funds to support the research, advocacy, and programs of the Arthritis Foundation. It is open to beginner and experienced riders who commit to a fundraising goal. More information is available at arthritis.org/CaliforniaCoastClassic.

The Arthritis Foundation is the Champion of Yes. Leading the fight for the arthritis community, the Foundation helps conquer everyday battles through life-changing information and resources, access to optimal care, advancements in science, and community connections. The Arthritis Foundations goal is to chart a winning course, guiding families in developing personalized plans for living a full life and making each day another stride towards a cure.

The Arthritis Foundations California Coast Classic Bike Tour, The Ride of a Lifetime, is one of four Arthritis Bike Classic events staged on the West Coast. It began in 2001 and is the flagship fundraising bike tour of the Arthritis Foundation, raising over one million dollars annually. Beginner and experienced cyclists are welcome on the 8-day, fully supported 525-mile journey down the coast of California from San Francisco to Los Angeles. For more information, please visit arthritis.org/CaliforniaCoastClassic.

See the rest here:
Arthritis Foundation's Coast Classic Bike Tour Changes Course - Aptos Times

Read More...

Kelly Osbourne Campaigning to Make Stem Cell Therapy Affordable in America – Hollywood.com

April 28th, 2017 3:40 pm

Wenn

Singer-turned-TV personality Kelly Osbourne wants to help cure fellow Lyme disease sufferers by making stem cell therapy available for all in the U.S.

Ozzy and Sharon Osbournes daughter contracted the condition after she was bitten by a tick during a party for the rockers 56th birthday back in 2004, when her mother had a reindeer sanctuary installed at their Los Angeles home.

However, Kelly wasnt properly diagnosed until 2014, months after suffering a seizure while filming an episode of E!s Fashion Police show in 2013, when doctors claimed her collapse had been caused by epilepsy.

She did some research into her ailments and discovered she was actually struggling with Lyme disease, and promptly sought out alternative treatment to help her overcome the illness.

I started to actually do the one thing doctors tell you not to do and thats to go online and look it up, she explained on Good Morning America, and all roads pointed to Lyme disease so I found a doctor through my mum.

I went to Frankfurt, Germany, and I did stem cell (therapy) and I got cured, Kelly claimed.

The 32-year-old is lucky to have been in a position to afford the treatment, which involves the transplant of stem cells to heal those damaged by the disease, and now she is looking to get involved in making the therapy more widely available and affordable to others less fortunate.

It sickens me that thats not available to everyone and that you have to be considered lucky or privileged to get that sort of treatment, she said. I want to make sure and I will do anything that I can do to make sure that that treatment is available in this country.

Kelly details her experience with the bacterial infection in her new memoir There Is No F**king Secret: Letters from a Bada** B**ch. She isnt the only celebrity to open up about her struggles with Lyme disease pop star Avril Lavigne, and veteran model Yolanda Hadid and her runway star kids Bella and Anwar Hadid have also been battling the illness.

View post:
Kelly Osbourne Campaigning to Make Stem Cell Therapy Affordable in America - Hollywood.com

Read More...

Banking Teeth for Stem Cell Therapy – HealthCentral.com

April 28th, 2017 3:40 pm

Banking Teeth for Stem Cell Therapy

Banking baby teeth or wisdom teetha practice thats been around for about 10 yearsis becoming more widely accepted in developed areas of the world, according to researchers. It involves cryopreserving teethand the dental stem cells they containfor potential stem cell therapy in the future.

Most research surrounding dental stem cells and tooth banking is still in the experimental stage and, at this time, scientists disagree about whether its worthwhileunlike cord blood banking, which has proven benefits for stem cell therapy. Some research suggests preserved dental stem cells could one day be used to regenerate healthy tissue and help fight complex diseases. But many experts remain less convinced of the potential benefits, as so much of the research is preliminary.

So far, the research has centered around dentinthe innermost hard layer of the tooth, below the enameland soft tissue beneath the dentin called pulp. The pulp contains the tooths nerve and blood supplies. In studying how teeth repair themselvesfrom a cavity, for exampleresearchers discovered that teeth contain stem cells. More studies are needed to determine if these dental stem cells can be harvested, preserved, stored, and someday used for stem cell therapy.

Image Credit: iStock

Sourced from: CNN

A new study suggests that cardiovascular decompensationa life-threatening drop in blood pressure caused by serious injuries involving significant blood lossmay be treated temporarily at the scene or during transport to the hospital simply by applying a bag of ice water to the injured persons face. Decompensation, which remains a dangerous complication even after bleeding has stopped, reduces the delivery of oxygen to the brain, heart, and other vital organs.

For the study, ten healthy volunteers were placed in a special chamber that simulates blood circulation after a person has lost one-half to one liter of blood and a tourniquet has been applied to stop the bleeding. Researchers applied bags of ice water or bags of room-temperature water to the study participants faces for 15 minutes while they continuously monitored cardiovascular function. They discovered that participants treated with bags of ice water experienced significant increases in blood pressure, suggesting that applying ice water can improve cardiovascular function after blood loss and prevent a dangerous drop in blood pressure.

Researchers expect to begin clinical trials soon. The hope is that this simple technique can be used by first responders or medics in the field of combat to improve survival rates after injuries involving blood loss by providing extra time for transport to a hospital or other medical facility.

Image Credit: iStock

Sourced from: ScienceDaily

Cooking dinner at homerather than eating outis a good way to eat healthier and save money, according to researchers at Oregon State University and the University of Washington. Historically, people with a higher socioeconomic status are generally healthier than those with lower incomes, but this study suggests otherwiseIF more money means dining out more often and less money means eating at home.

The study involved about 400 adults in the Seattle-area. Study participants were surveyed about their cooking and eating behaviors for one week and provided various socioeconomic information. Their weekly food intake was graded using the Healthy Eating Index (HEI)a scale that ranges from 0 to 100, with higher scores indicating a healthier diet.

According to researchers, cooking at home three times per week produced an average score of about 67 on the Healthy Eating Index, and cooking at home six times per week resulted in an average score of 74. Results of the study suggest that home-cooked dinners are associated with a diet lower in calories, sugar and fat, overall than dining out regularly.

Image Credit: iStock

Sourced from: Oregon State University

Daily Dose Index

See the original post:
Banking Teeth for Stem Cell Therapy - HealthCentral.com

Read More...

Overcoming diabetes through churches in Columbia’s African-American community – Columbia Missourian

April 27th, 2017 10:45 am

COLUMBIA Verna Laboy's paternal grandmother lost both legs to diabetes complications. Very recently, one of her cousins lost a leg also to diabetes. Yet another cousin is on dialysis, a complication of the same disease.

"This is personal for me," she says.

She doesn't pretend to be an expert that's not where the passion comes from. She, herself, was "on the fast track" to diabetes and has found it hard to stick with an exercise or diet.

All of that has made Laboy a passionate force behind Live Well By Faith, a wellness program launched one year ago through the Columbia/Boone County Health and Human Services Department for black churches in Boone County.

Data from a county-wide survey in 2013 showed that of the 9,300 people living with diabetes in Boone County, black people were four times more likely to die from complications related to the disease than their white counterparts. Nationally, black women are just under two times more likely than white women to die from diabetes complications, while black men are about one and a half times more likely than white men to die from diabetes complications, according to the Centers for Disease Control and Prevention.

Type 2 diabetes the more common form of the chronic disease occurs when the level of blood glucose (sugar) in a person's body is higher than normal because insulin ceases to be produced properly, according to theAmerican Diabetes Association. As a result, the body's cells are starved for energy and the eyes, kidneys, nerves and heart can be effected. Factors associated with diabetes include obesity, a family history of the disease and race and ethnicity.

Verna Laboy saves leftover food April 2 after the Live Well By Faith cooking class. Laboy runs the Live Well By Faith wellness program through St. Luke United Methodist Church in Columbia, which aims to address health disparities in minority communities through church programs.

Laboy, a self-proclaimed "health evangelist" and community activist, has been working with black churchgoers since April 2016 to educate people about the consequences of unhealthy lifestyles, to encourage healthy eating and to provide programsfor long-term success in health management.

"Food is important to this culture, and it's cooked the wrong way. It's a lethal digestion," Laboy said. "It's an addiction that needs to be addressed, a very unhealthy addiction. We need to increase our health literacy."

Laboy uses the word "bulldozer" to describe how she's paving the way towards bringing down the rates of diabetes and heart disease among blacks in Boone County.

"I don't have a health background. I'm not a personal trainer. I'm not a nutritionist," she said.

Her own struggle to change her lifestyle has been a source of insight.

"But I've been on this journey for years, unable to stay consistent," she said.

She and other "health ministers" at the Live Well By Faith-accredited churches are "looking for people that are dealing with the challenges themselves to adopt (healthy) behaviors and see the changes and take people on the journey with them," she said.

Laboy enthusiastically and passionately evangelizes on a healthy lifestyle.

"Verna's not doing the work," she said, slipping into third person, as she often does. "You have to do the work. This is your church. This is your congregation. This is your family. This is your life."

Diabetes can lead to high blood pressure, heart disease, amputations and death if not managed well, according to the American Diabetes Association.

Lifestyle factors and genetics are the primary influences of type 2 diabetes, according to a study published in 2012. Type 2 diabetes involves insulin resistance and declining insulin production and components of the disease include physical inactivity, sedentary lifestyle, cigarette smoking and a generous consumption of alcohol.

Maintaining a healthy diet for the prevention or treatment of diabetes combined with physical activity is associated with lowered risks of diabetes, according toa study published by the Journal of Education and Health Promotion. Eating smaller serving sizes and cutting calories improves insulin sensitivity, and regular physical activity helps with weight loss and may also decrease blood pressure.

Increasinghealth literacy entails learning about what types of foods are recommended for healthful living, what types of food to avoid and fitness.Focusing meal planning around nutrient dense foods such as vegetables, beans, whole grains, fruit, non-fat dairy, fish and lean meats is one way to decrease the risk of diabetes, according to theAmerican Diabetes Association.

But the church is an especially important institution for many black Americans.

From left, Frances Logan, Shae Brown and Mary B. Warren wash their hands during the Live Well By Faith cooking class April 2 in Columbia. Each attendee washed their hands for 20 seconds, which was a technique they reviewed at the start of the workshop.

Annabelle Simmons, a health minister at St. Luke United Methodist Church, joined the Live Well By Faith team . After she took a healthy lifestyle class through the program, she said her eyes were opened about health.

But she wasn't sure exactly which of the possible Life Well by Faith courses she would teach.

There it was: "Cooking Matters." She thought to herself, "I know how to cook," but had to become certified to teach it. That entailed learning about how to hold a knife properly, how to slice correctly, among other kitchen skills.

The healthy cooking and eating topics changed her habits: learning how to read food labels, how much food is in a serving, the calorie count, the protein count, etc. "And now, every time I go shopping, I'm looking at the labels, so I know it works," she said.

The class also teaches people how to cook healthy food on a budget, Laboy said: "They can see how cheap they can cook good food, healthy food."

In addition to what she learned in "Cooking Matters," Simmons also learned how to take a blood pressure reading, which she does on Sundays free if church members ask her to do so. The health ministers at St. Luke also signed off on a water policy, requiring that water be offered with every meal offered at a church event.

"People were going, 'But I want punch, I want coffee,'" Simmons said.

A "no fried foods" policy is also in place.

And yet, people still gather around the table.

"We get to fellowship with one another around food, preparing the food together," Simmons said.

Dee Campbell-Carter, a lifestyle coach for the health ministry at Friendship Missionary Baptist Church, said the church will start a "Cooking Matters" class later this year. The health ministry at Friendship Baptist offers blood pressure checks every second and fourth Sunday before and after service lets out as well as "SweatSuit Sundays," when the congregation stops in the middle of service to do high- and low-impact exercises to gospel music.

"The thing we're doing is building a faith community that's cross-pollinating," Laboy said. This means that if a class is offered at one church, all the other churches are invited to send participants.

Dee Campbell-Carter, left, and Dorothy Slaughter tend to a garden plot April 17 at Friendship Baptist's community garden. Campbell-Carter is in charge of the garden, which came to fruition in January.

As the sun set last week, Campell-Carter strolled between garden plots behind Friendship Missionary Baptist filled with budding greens, tomatoes and peppers while bees hovered over dandelion-covered grass. Campbell-Carter and community member Dorothy Slaughter tilled the soil, pulling weeds and watering mustard and collard greens and kale.

The garden is called "Friendship Gardens," and the food harvested in the plots will be used in the "Cooking Matters" class when it begins.

Half-built garden beds lay ready for the next stage: being raised on stilts for planting. They will be waist high to accommodate children or those who are wheelchair bound, Cambell-Carter said.

The garden is a placewhere church memberscan grow healthy produce to take home and cook.

Cambell-Carter described Slaughter as the go-to gardener. She taught the community how to dig weeds out from their root with a simple tools like a plastic knife, and that coffee grounds are a good fertilizer and deterrent for some pests.

Calvin Miles, another member of Friendship Baptist Church, is the handy man on site. He put the finishing touches on the community garden sign his son painted that will stand over their "harvest trailer." He also built the raised flats for youth or those with disabilities.

Healthy food fits with his spiritual life, Miles said: "Body, mind and spirit. They all come together."

Calvin Miles paints Friendship Missionary Baptist's Friendship Garden sign on April 17. Miles' son painted the majority of the sign, while Miles added the finishing touches.

"When I see things like (Friendship Gardens) take offit's just everything," Laboy said.

But not every health ministry takes root as easily nor does every program.

Paula Williams chaired the board for the Boone County Minority Health Network until it disbanded last year. The network began in 2005 with the purpose of addressing health disparities. It ultimately died due to lack of funding.

"There was no full-time, dedicated staff to keep up with the grant writing," Williams said.

Live Well By Faith is on a two-year grant from the Boone County Commission, and Laboy is optimistic about getting it renewed. "I'm letting anyone out there that's doing this kind of work know that Verna is available to take this to the next level," she said.

There's one year left on the grant. Then, the Columbia/Boone County Department of Public Health and Human Services will re-apply. "We are just getting started," Laboy said.

She recognizes that it takes time to change a culture.

"We have to make different choices," she said. "We're living longer. Do you want to live in a nursing home? Do you want illness to take you out in such a way where someone who doesn't want to take care of you is forced to take care of you? It's a tough conversation to have, but someone has to put it out there."

Churches around Boone County are having that conversation. Laboy hopes "Cooking Matters" will be offered in 15 African-American churches in the upcoming year. Urban Empowerment Ministries has a Weight Watchers program with 22 members representing five different church communities.

Five other churches are interested in the upcoming "Eat Healthy, Be Active" program, Laboy said. She and six trained lifestyle coaches from those health ministries will be meeting to talk about bringing the curriculum to those five churches. The Columbia/Boone County Department of Public Health and Human Services has a "Shazzy Fitness" program that brings community members together to work out to gospel music.

"These are small ways we're chipping away at the health literacy and health consciousness of people," Laboy said.

Dorothy Slaughter removes weeds from her garden plot on the evening of April 17. The garden, a part of the Live Well By Faith program at Friendship Missionary Baptist Church, is open to community members to grow healthy produce to use in their meals.

"This is the hardest work I've ever done," Laboy said. "And it's taking care of myself. Why is that so hard to do? Because we're going against the grain; it's going against the culture," she said. "Great-grandma made the biscuits this way. Grandma made the greens this way. Mom makes the cobbler this way. So our tastes have adjusted, but it's killing us."

There are healthier ways of doing things, Simmons said. "You start developing a habit of being healthy rather than choosing the cake. It's been a long time since I've had cake, now. I want cake; I love cake! But it's an unhealthy choice."

Laboy shared similar sentiments. "You've got to be able to tell yourself no," she said.

"This is a lifestyle transformation change for me and I have to do it. If no one else does it, Verna has to show up for Verna."

Laboy shares her experiences on the Live Well By Faith Facebook page regularly, reminding those who are on the journey with her that they can succeed even if some days are hard. "Victory I make it to the gym this morning and boy was it a struggle. I wanted to quit!" she shared in a recent post.

"Setbacks are set-ups for a come back!" she wrote in an earlier post.

Campbell-Carter faced a setback as well. "I had to creatively regroup my workout plan when my (Activity and Recreation Center) membership expired last December," she said. Her insurance stopped reimbursing her for the membership, but she said she knew she wanted to stay active.

Campbell-Carter ultimately chose to start budgeting for weekend classes, and during the week she does yoga, gardening or goes on a "PRAYER walk," which is the term used in the Friendship Baptist health ministry to describe a neighborhood walk a group or individual can participate in. "It's great to feel increases in my muscle strength and tone. Also, I sleep so good at night," she said.

Laboy sees the proof at the gym, not just in herself but in others.

"When I'm at the gym working out and I see some of my diabetes self-management folks walking around on the track or working out on the equipment, my heart just smiles," she said.

But there's so much more to do."I can't just plant the seed and leave," Laboy said. "I have to keep coming back and watering it, and when I come, I'm coming with a tank of water and fertilizer."

View original post here:
Overcoming diabetes through churches in Columbia's African-American community - Columbia Missourian

Read More...

Smartphone-Controlled Cells Keep Diabetes In Check – IEEE … – IEEE Spectrum

April 27th, 2017 10:45 am

Smartphones can already control homes and cars, anddiagnosediseases. Chinese and Swiss researchers now show that a smartphone can command engineered cells implanted in diabetic mice to produce insulin.

The researchers demonstrated a clever closed-loop system in which a digital glucometer transmits data on the rodents blood glucose levelsto a smartphone, which processes the data and then signals the implanted cells to deliver insulin.This is a step towards a new era of personalized, digitalized precision medicine, says Haifeng Ye of East China Normal University,who led the work reported in Science.

Cell-based therapies are a radical new medical treatment option being investigated by researchers. The idea is to turn cells into disease-fighting weapons by engineering them to produce therapeutic chemicals and proteins that they would churn out once implanted in the body. Living white blood cells, for instance, have been designed to fight cancer, HIV, and other diseases.Hundreds of cell therapies are undergoing clinical trials. But none can be controlled from outside the body.

Ye and his colleagues have come up with an innovative way to add smarts to cell-based therapy. They chose diabetes as the target disease.

They initially inserted light-sensitive bacterial proteins into mammalian cells. When exposed to far-red light (wavelength of about 730 nanometers), the protein activateda genetic pathway that causedthe cells to produce insulin.

After that success, they team made dime-sizedevices in which circular power-receiving coils surround a hydrogel that is embedded with the engineered cells and far-red LEDs. These devices were implanted under the skin of diabetic mice. When an external transmitting coil wirelessly switches on the LEDs via electromagnetic induction, their light triggers the cells to produce insulin in the animals.

The team made three things to remotely control the engineered cells: a custom-engineered Bluetooth-active glucometer,an Android-based smartphone app,and an intelligent control box that controls the power-transmitting coil.

When the researchers placemice blood samples on the glucometer, it sends measurements to the smartphone via Bluetooth. The phone app compares these levels to a pre-set threshold, then signals the control box to turn on the power-transmitter coil, which switches on the LEDs long enough for the cell implant to deliver the right amount of insulin.

The animals blood glucose typically went down to nondiabetic levels within two hours of irradiation. The system maintained the blood glucose concentration in mice for 15 days without any side effects. After that it could be replaced, Ye says, but a much longer performance or replacement frequency of the implant needs to be further investigated in humans.

One big limitation of the system is that it needs manual blood draws. Another is that the animals need to be close to the transmitting coil and be exposed to EM radiation to switch on the LEDs.

But a bit more engineering could yielda diabetesmonitoring-and-treatment system that isfully automatic and portable. A continuous glucose monitorcould send blood sugar measurements to the users phone. The phone would trigger a battery-powered LED wristband to shine light on the implanted insulin-producing cells.

IEEE Spectrums biomedical engineering blog, featuring the wearable sensors, big data analytics, and implanted devices that enable new ventures in personalized medicine.

Sign up for The Human OS newsletter and get biweekly news about how technology is making healthcare smarter.

Forget manual pipetting: These companies say biology needs software, programming languages, and, of course, robots 27Apr

U.S. Department of Defense backs peripheral nerve stimulation as a tool to improve learning and military skills 26Apr

Facebook promises 100 words per minute, but doesn't detail the technology that can pull that off 20Apr

Electrical stimulation delivered to the human brain when memory is predicted to fail can improve memory 20Apr

Two new studies show good results on DBS for depression, but the treatment is still far from clinical use 18Apr

Machine learning uses data from smartphones and wearables to identify signs of relationship conflicts 18Apr

What can we expect from Neuralink, the new Elon Musk company devoted to brain-computer interfaces? 12Apr

Algorithms spot heart failure, lung cancer, and drug candidates sooner 5Apr

The heart hugger, the drug doser, and flexible forceps show how malleable machines will work safely inside the body 31Mar

In Rwanda, the drone delivery startup Zipline is now bringing blood across mountains 31Mar

This lab-on-a-glove puts weapons detection on the user's fingertips 30Mar

The electronic skin is touch-sensitive and could be inexpensively manufactured 30Mar

Harvard's home testing kit for male fertility would just need your smartphone and semen sample 23Mar

Stanford researchers design Lego robot kit so students can automate their chemistry experiments 22Mar

Her device uses near-infrared to provide MRI-resolution imaging in a cheap wearable 15Mar

A clinical trial in Switzerland is testing a spinal implant to help paralyzed people walk again 14Mar

Project that aims to build a synthetic yeast pioneers the design and debugging of chromosomes 10Mar

Molecular robot brings us one step closer to mimicking cellular behavior 7Mar

With new design advances, nanorobots are inching closer to medical use 1Mar

This sleek yet rugged sensor measures better and lasts longer 27Feb

See more here:
Smartphone-Controlled Cells Keep Diabetes In Check - IEEE ... - IEEE Spectrum

Read More...

Decrease in cardiovascular diseases benefits persons with diabetes … – Science Daily

April 27th, 2017 10:45 am

The incidence of cardiovascular diseases in Sweden has decreased sharply since the late 1990s. These are the findings of a study from Sahlgrenska Academy which included almost three million adult Swedes. In relative terms, the biggest winners are persons with type 1 and type 2 diabetes.

"This is a huge improvement and a testament to the improvements in diabetes and cardiovascular care throughout Sweden," says Aidin Rawshani, medical doctor and doctoral student in molecular and clinical medicine.

The study, which was published in The New England Journal of Medicine, shows that the incidence of cardiovascular diseases and deaths among individuals with diabetes in Sweden dropped significantly between 1998 and 2014. The population in general exhibited the same trend, albeit to a smaller extent.

Among persons with type 1 diabetes, with an average age of 35 years, the incidence pf cardiovascular disease was reduced by 40 per cent during the period in question. In the control group of persons of similar age but without diabetes, the decrease was 10 per cent.

Among individuals with type 2 diabetes, with an average age of 65 years, the incidence of cardiovascular disease decreased by 50 per cent. Among control persons of similar age without diabetes, the decrease was 30 per cent.

Surprising results

"We were surprised by the results, specially for persons with diabetes. Some smaller studies in the past have indicated that numbers were improving, but nothing of this magnitude," says Aidin Rawshani.

In total, approximately 2.96 million individuals were studied, of which 37,000 had type 1 diabetes and 460,000 had type 2 diabetes. The results of the study are based on linked processing of data from the National Diabetes Register, the Cause of Death Register and the part of the Patient register that concerns inpatient care.

In addition to matching by age and gender, the groups that were compared were also matched geographically using register data from LISA (the longitudinal integration database for health insurance and labour market studies).

The deaths that took place in the groups during the study period were almost exclusively related to cardiovascular disease. Individuals with diabetes have previously shown to suffer a risk of cardiovascular disease and early death that was between two and five times as high as in the general population.

Better risk control

"One of the main findings of the study is that both deaths and the incidence of cardiovascular disease is decreasing in the population, both in matching control groups and among persons with type 1 and type 2 diabetes. One paradoxical finding is that individuals with type 2 diabetes have seen a smaller improvement over time regarding deaths compared to the controls, while persons with type 1 diabetes have made an equal improvement to the controls," notes Aidin Rawshani.

The positive trends that have been observed in the study are most likely due to an increased use of preventative cardiovascular medicines, advances in the revascularisation of atherosclerotic disease and improved use of instruments for continual blood sugar monitoring, and the fact that Swedish diabetes care has generally worked well with good treatment guidelines and quality assurance efforts.

"Out study and analysis does not include explanations of these trends, but we believe that it is a matter of better control of risk factors, better education patients, better integrated treatment systems for individuals with chronic illnesses and individual care for persons with diabetes. There is often an entire team working with a patient, ensuring that their needs are met," says Aidin Rawshani.

Story Source:

Materials provided by University of Gothenburg. Note: Content may be edited for style and length.

Read the original post:
Decrease in cardiovascular diseases benefits persons with diabetes ... - Science Daily

Read More...

Lilly Assures Market As Diabetes Stumbles – Seeking Alpha

April 27th, 2017 10:45 am

As the diabetes wars have raged, Eli Lilly's (NYSE:LLY) balanced portfolio has helped insulate it from the share price losses dealt to competitor Novo Nordisk (OTCPK:NONOF). But even Lilly can have an off quarter.

Trulicity's growth was more than offset by below-consensus sales for Basaglar and Jardiance - the underperformance of the last of these was surprising given that it has begun marketing on its cardiovascular benefit. When combined with last week's US rejection of rheumatoid arthritis entry Olumiant, these disappointments forced Lilly executives to reassure investors that the company's medium-term guidance of 5% growth could still be met.

Lilly shares fell 3% today following the release of first-quarter results, removing $2.7bn in market valuation. Since the Olumiant complete response letter was announced, shares have fallen 6% (Olumiant setback opens the door to rivals, April 18, 2017).

Bernstein analyst Tim Anderson chalked up some of the losses to profit-taking - before the Olumiant news, shares were up 16% on the year - but acknowledged the effect of Olumiant and diabetes revenue on investor sentiment.

Topline good

In the long view, the Indiana-based group had a positive quarter, with revenue of $5.2bn and earnings per share of $0.98 in line with investor expectations. However, having just got over the news of Olumiant - rejected because of questions over the most efficacious dose and safety characterization - news that diabetes was not necessarily firing on all cylinders was not taken well.

Expectations for Jardiance remain high since it is the first of the SGLT2 class to be allowed to market on the basis of averting cardiovascular death in diabetics, although it could very well be chased by competitors Invokana, from Johnson & Johnson, and Farxiga, from Astrazeneca (NYSE:AZN) (ACC - Jardiance heart benefit looks like a class effect, March 20, 2017).

Lilly diabetes chief Enrique Conterno characterized the SGLT2 class as having flat growth before the cardiovascular data was included on the Jardiance label, but said that since marketing on that claim has begun new patient starts have risen 70% - the miss on Jardiance sales may simply reflect a mismatch between investor expectations and market realities.

Olumiant's bigger setback has investors questioning the 5% revenue growth forecast given that the drug is one of four new products that will post annual sales growth of $1bn or more to counteract losses due to patent expiries. Finance chief Derica Rice offered some comfort: "We've factored in that we won't have 100% success on every molecule" when preparing that forecast, he said.

Olumiant's failure to add US revenue does, however, increase the pressure on the rest of the portfolio to meet sales expectations. And Lilly's exposure to the volatile diabetes space raises the risk that that will not happen.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

Read more here:
Lilly Assures Market As Diabetes Stumbles - Seeking Alpha

Read More...

One in 7 people in Nevada is living with diabetes, and the state is … – Yahoo Finance

April 27th, 2017 10:45 am

(Sen. Yvanna Cancela speaks with Majority Leader Aaron Ford and diabetes patients.Courtesy Yvanna Cancela) The state of Nevada is taking a new approach to tackling the rising price of prescription drugs with a new bill.

The bill, introduced in March by state Senator Yvanna Cancela, has already faced opposition from lobbyists and nonprofit patient groups that disagree with the bill's approach to reining in prescription drug spending.

Nevada is one of 23 states with proposed legislation to take on the rising cost of prescription drugs. But unlike others that focus on drug prices in a general sense, Cancela's bill focuseson two specificgroups of drugs that are used to treat diabetes: insulin and biguanides.

It's the latest milestone in government actions at the local, state, and national levels that attempt to change the way wespend money on prescription drugs.

Diabetes is a group of conditions in which the body can't properly regulate blood sugar that affects roughly 30 million people in the US. And for many people living with diabetes including the1.25 million people in the US who have Type-1 diabetes injecting insulin is part of the daily routine.

insulin prices humalog novolog V2

(The list price of Humalog and Novolog, two short-acting insulins, over 20 years. The list prices don't factor in any rebates or discounts the drugmaker pays out.Andy Kiersz/Business Insider) Insulin, a hormone thathealthy bodies produce, has been used to treat diabetes for almost a century, though it's gone through some modifications. In the past few years, the list price of insulin has increased routinely.

The list price of the most commonly used insulins have increased roughly 300% over the last decade. Technically, there's no "generic" insulin, though a cheaper version of a long-acting insulin did come on the market in 2016. There are cheaper medications forbiguanides, such as metformin, which are used to treat Type-2 diabetes.

Before becoming a state senator, Cancela workedas a director for the Culinary Workers Union in Las Vegas, which represents about 60,000 workers. The union pays for its members health insurance through a self-funded trust, which Cancela told Business Insider gave the organization a lot of access to details about how its health funds were being spent. One of the drugs she noticed was becoming a problem for members was insulin.

There are roughly 281,000 adultsliving in Nevada, or 12% of the total population, that have one of the two types of diabetes, with another 39% in the prediabetes stage, in which blood glucose levels are elevated but not to the point of type-2 diabetes. Because diabetes is one of the biggest medical problems in Nevada, Cancela said, it made for a perfect starting point to introduce legislation.

The Nevada bill, known as SB265, takes four mainapproaches to confronting the drugmakers that make insulin and biguanides to treat diabetes.

Like most legislation that tries to rein in prescription drug spending, SB265 is facing its fair share of pushback and criticism.

Cancela said there's been around 70 lobbyists who have come in for the session to oppose the bill, which is more than double the number present for Nevada's 2015 session,according to The Nevada Independent. There's also been a number of patient groups that have spoken out as well, including those representing people with lupus and epilepsy.

"Proposed legislation in the Nevada State Senate unfairly targets people with diabetes, would be a major windfall for health insurance companies, and leaves patients wondering whos next," Lupus of Nevada said in a Facebook post. "Were specifically worried that Nevadans with Lupus could be singled out."

Read More

(A Type 1 diabetes patient holds up bottles of insulin.Reuters/Lucy Nicholson) Nine pharmaceutical companies submitted lettersin opposition to the bill, as well as pharma's lobbying group PhRMA and biotech's lobbying group BIO. Many brought up their opposition to disclosingmore information about how they set their prices.

A letter from Novo Nordisk a company that manufactures insulin and other diabetes medications argued that the bill doesn't take into account the rebates drug companies pay out to middlemen. That issue was raised in a number of the letters opposing the bill.

"This proposal would impose significant new, complex and punitive requirements on drug manufacturers when manufacturers already provide competitive discounts to payers and represent only a single component of the enormously complex US drug pricing and distribution system," the company said in the letter. "This complexity, which the proposed legislation fails to address, has resulted in confusion around what patients pay for medicines."

To be sure, there's more to the story than just the list price a manufacturer sets. Along the way, there are as many as five companies that have a stake in the price of a medication. But there's a lack of transparency about the portion each player gets. To counter that, some drug companies have started disclosing their net prices, or the amount it actually receives in return for the drug after factoring in any rebates or discounts paid out to middlemen.

Sanofi noted in its opposition letter that its net price for Lantus, a long-acting form of insulin, fell over five years.

Sanofi said in a statement to Business Insider:

"Sanofi believes this legislation will fail to achieve its intended purpose and may actually restrict patients access to important medications. As a company founded on and committed to science and improving health, we understand that affordability and access to our products is critical for patients and society, and we are committed to working with all stakeholders to ensure patients have affordable access to the treatments they need in a system that is sustainable and continues to promote ongoing investments in science and innovation."

Others, like Ken Thorpe, the chairman of the Partnership to Fight Chronic Disease (a group that partners witha number of healthcare companies and patient organizations) and a health policy professor at Emory University, criticizedthe idea that the bill is a way to help those living with diabetes. He argued in a piece in the Nevada Appeal that the price capswon't keep people from getting diabetes.

"If they're really trying to get the cost of healthcare to grow at a slower rate, this is not the way," he told the Appeal. Instead, he said, there should be more of a focus on preventing diabetes.

Cancela said that's something she's working on as well, calling SB265 "one piece of the puzzle." She has another piece of legislation that would promote urban agriculture to increase access to healthy foods in low income communities.

The bill is still with the Health and Human Services committee, meaning it needs to clear the Assembly and Senate before it makes its way to the governor.

But of course, drug price bills have failed in the past. In November 2016, Californians voted against a proposition that would've capped prescription drug prices at what the Department ofVeterans Affairs pays for them.

Cancela understands that it's not going to be an easy ride.

"We're trying to do something that's never been done before," Cancela said.

NOW WATCH: Scott Galloway on the biggest thing in tech in 2017: Amazon could eliminate the existence of brands with voice technology

More From Business Insider

Read more:
One in 7 people in Nevada is living with diabetes, and the state is ... - Yahoo Finance

Read More...

Type 1 Diabetes Mellitus Forecast in 12 Major Markets 2017-2027 … – Yahoo Finance

April 27th, 2017 10:44 am

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "Type 1 Diabetes Mellitus Forecast in 12 Major Markets 2017-2027" report to their offering.

Type 1 Diabetes Mellitus (T1DM) is a multisystem disease that progressively destroys the pancreas' ability to produce insulin. This leads to a chronic condition of defective metabolism of fat, carbohydrates and proteins due to the lack of insulin. It occurs mainly in childhood and adolescents, however a rising number of latent autoimmune diabetes of adulthood (LADA) cases have been reported mainly due to a better understanding and diagnosis of the disease.

This report provides the current prevalent population for Type 1 Diabetes Mellitus across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China and Russia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Type 1 Diabetes Mellitus have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Reasons to Buy:

- Able to quantify patient populations in global Type 1 Diabetes Mellitus market to target the development of future products, pricing strategies and launch plans.

- Gain further insight into the prevalence of the subdivided types of Type 1 Diabetes Mellitus and identify patient segments with high potential.

- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

- Provide a level of understanding on the impact from specific co-morbid conditions on Type 1 Diabetes Mellitus prevalent population.

- Identify sub-populations within Type 1 Diabetes Mellitus which require treatment.

- Gain an understanding of the specific markets that have the largest number of Type 1 Diabetes Mellitus patients.

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key Comorbid Conditions/Features associated with the disease

8. Methodology for quantification of patient numbers

9. Top-line Prevalence for Type 1 Diabetes Mellitus

10. Features of Type 1 Diabetes Mellitus Patients

10.1 Comorbidities and Sequelae in T1DM Patients

10.2 T1DM patients with Retinopathy

10.3 Prevalence of T1DM defining antibodies

11. Abbreviations used in the report

12. Patient-Based Offering

13. Online Pricing Data and Platforms

14. References

15. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/j3bqpv/type_1_diabetes

View source version on businesswire.com: http://www.businesswire.com/news/home/20170427005670/en/

Read the original:
Type 1 Diabetes Mellitus Forecast in 12 Major Markets 2017-2027 ... - Yahoo Finance

Read More...

Genes need to be screened for stem cell transplants – Science Daily

April 27th, 2017 10:42 am

Regenerative medicine using human pluripotent stem cells to grow transplantable tissue outside the body carries the promise to treat a range of intractable disorders, such as diabetes and Parkinson's disease.

However, a research team from the Harvard Stem Cell Institute (HSCI), Harvard Medical School (HMS), and the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard has found that as stem cell lines grow in a lab dish, they often acquire mutations in the TP53 (p53) gene, an important tumor suppressor responsible for controlling cell growth and division.

Their research suggests that genetic sequencing technologies should be used to screen for mutated cells in stem cell cultures, so that cultures with mutated cells can be excluded from scientific experiments and clinical therapies. If such methods are not employed it could lead to an elevated cancer risk in those receiving transplants.

The paper, published online in the journal Nature on April, 26, comes at just the right time, the researchers said, as experimental treatments using human pluripotent stem cells are ramping up across the country.

"Our results underscore the need for the field of regenerative medicine to proceed with care," said the study's co-corresponding author Kevin Eggan, an HSCI Principal Faculty member and the director of stem cell biology for the Stanley Center. Eggan's lab in Harvard University's Department of Stem Cell and Regenerative Biology uses human stem cells to study the mechanisms of brain disorders, including amyotrophic lateral sclerosis, intellectual disability, and schizophrenia.

The research, the team said, should not discourage the pursuit of experimental treatments but instead be heeded as a call to screen rigorously all cell lines for mutations at various stages of development as well as immediately before transplantation.

"Our findings indicate that an additional series of quality control checks should be implemented during the production of stem cells and their downstream use in developing therapies," Eggan said. "Fortunately, these genetic checks can be readily performed with precise, sensitive, and increasingly inexpensive sequencing methods."

With human stem cells, researchers can recreate human tissue in the lab. This enables them to study the mechanisms by which certain genes can predispose an individual to a particular disease. Eggan has been working with Steve McCarroll, associate professor of genetics at Harvard Medical School and director of genetics at the Stanley Center, to study how genes shape the biology of neurons, which can be derived from these stem cells.

McCarroll's lab recently discovered a common, precancerous condition in which a blood stem cell in the body acquires a pro-growth mutation and then outcompetes a person's normal stem cells, becoming the dominant generator of his or her blood cells. People in whom this condition has appeared are 12 times more likely to develop blood cancer later in life. The study's lead authors, Florian Merkle and Sulagna Ghosh, collaborated with Eggan and McCarroll to test whether laboratory-grown stem cells might be vulnerable to an analogous process.

"Cells in the lab, like cells in the body, acquire mutations all the time," said McCarroll, co-corresponding author. "Mutations in most genes have little impact on the larger tissue or cell line. But cells with a pro-growth mutation can outcompete other cells, become very numerous, and 'take over' a tissue. We found that this process of clonal selection -- the basis of cancer formation in the body -- is also routinely happening in laboratories."

To find acquired mutations, the researchers performed genetic analyses on 140 stem cell lines -- 26 of which were developed for therapeutic purposes using Good Manufacturing Practices, a quality control standard set by regulatory agencies in multiple countries. The remaining 114 were listed on the NIH registry of human pluripotent stem cells.

"While we expected to find some mutations in stem cell lines, we were surprised to find that about five percent of the stem cell lines we analyzed had acquired mutations in a tumor-suppressing gene called p53," said Merkle.

Nicknamed the "guardian of the genome," p53 controls cell growth and cell death. People who inherit p53 mutations develop a rare disorder called Li-Fraumeni Syndrome, which confers a near 100 percent risk of developing cancer in a wide range of tissue types.

The specific mutations that the researchers observed are "dominant negative" mutations, meaning, when present on even one copy of P53, they are able to compromise the function of the normal protein, whose components are made from both gene copies. The exact same dominant-negative mutations are among the most commonly observed mutations in human cancers.

"These precise mutations are very familiar to cancer scientists. They are among the worst P53 mutations to have," said Sulagna Ghosh, a co-lead author of the study.

The researchers performed a sophisticated set of DNA analyses to rule out the possibility that these mutations had been inherited rather than acquired as the cells grew in the lab. In subsequent experiments, the Harvard scientists found that p53 mutant cells outperformed and outcompeted non-mutant cells in the lab dish. In other words, a culture with a million healthy cells and one p53 mutant cell, said Eggan, could quickly become a culture of only mutant cells.

"The spectrum of tissues at risk for transformation when harboring a p53 mutation include many of those that we would like to target for repair with regenerative medicine using human pluripotent stem cells," said Eggan. Those organs include the pancreas, brain, blood, bone, skin, liver and lungs.

However, Eggan and McCarroll emphasized that now that this phenomenon has been found, inexpensive gene-sequencing tests will allow researchers to identify and remove from the production line cell cultures with concerning mutations that might prove dangerous after transplantation.

The researchers point out in their paper that screening approaches to identify these p53 mutations and others that confer cancer risk already exist and are used in cancer diagnostics. In fact, in an ongoing clinical trial that is transplanting cells derived from induced pluripotent stem cells (iPSCs), gene sequencing is used to ensure the transplanted cell products are free of dangerous mutations.

View original post here:
Genes need to be screened for stem cell transplants - Science Daily

Read More...

New Eye Test Could Spot Glaucoma and Prevent Blindness in Millions – Newsweek

April 27th, 2017 10:42 am

A new eye test could prevent glaucoma, the biggest cause of irreversible blindness, by spotting symptoms before loss of sight begins.

Researchers at University College London (UCL) have developed an eye exam that could detect individual nerve cell death at the back of the eye a decade before symptoms present themselves.

Glaucoma affects 16 million people worldwide, many of whom have lost a third of their vision before they start treatment. The disease causes changes to the pressure inside the eye which kills the retinas nerve cells.

Subscribe to Newsweek from $3.25 per week

Early detection would allow doctors to start treatment before the patient begins to go blind. The new test uses a fluorescent dye that sticks to cells that are about to die. White fluorescent dots on the retina would reveal whether the patient has early-onset glaucoma.

Eye with acute angle-closure glaucoma, a sudden elevation in intra-ocular pressure that occurs when the iris blocks the eye's drainage channel. Jonathan-Trobe-Wikicommons

The test could also diagnose early-onset degenerative neurological conditions, such as Parkinsons, Alzheimers and multiple sclerosis.

The exam is still in its first trial phase and has so far only been tested on 16 people, but the initial results are promising, according to the study published in the medical journal Brain.

For the first time, we have been able to show individual cell death and detect the earliest signs of glaucoma. While we cannot cure the disease, our test means treatment can start before symptoms begin, lead researcher Professor Francesca Cordeiro of the UCL Institute of Ophthalmology said in a release published alongside the study.

Bethan Hughes, a spokesperson for the medical charity Wellcome Trust which funded the research, said: This innovation has the potential to transform lives for those who suffer loss of sight through glaucoma, and offers hope of a breakthrough in early diagnosis of other neurodegenerative diseases.

Read more:
New Eye Test Could Spot Glaucoma and Prevent Blindness in Millions - Newsweek

Read More...

New tool to combat avoidable blindness – AOP

April 27th, 2017 10:42 am

Peek Retina smartphone adapter launches

27 Apr 2017 by John White, Laurence Derbyshire

It has been a long and very challenging road to get to this point. Although there is much to celebrate, this is only the beginning of the journey. So explained Dr Andrew Bastawrous, co-founder and CEO of Peek, at the launch of Peek Retina at the London School of Hygiene and Tropical Medicine (20 April).

The device is the latest solution created by Peek, a social impact enterprise that works to give healthcare providers the tools and knowledge needed to deliver high quality, sustainable care.

The smartphone camera adapter is used for retinal imaging, which has been designed to help increase access to care by enabling more eye examinations to be carried out.

Described by the company as intuitive and easy to use, the tool enables the examination of the optic nerve and macula.

In a statement, Peek said: In a perfect world, retinal imaging would be standard practice at the point of initial examination, but it is not normal practice because retinal images are hard to capture using traditional equipment. We believe Peek Retina can make a significant impact on avoidable blindness by removing barriers to access and enabling new examinations to be performed, but we are calling on users and supporters to give as much feedback as possible so it can be made even better.

Peek Retina clips over the camera on any smartphone, enabling users to capture an image of the back of the retina and share it easily without the need for a desktop retinal camera.

The eye needs to be dilated to enable examination, with Peek highlighting that different countries have different rules governing the use of dilation drops. Once the eye is dilated, images of the retina can be captured without requiring a high skill level, although specialist skills and knowledge are needed to interpret the images, the company notes.

Other projects from Peek include Peek Acuity, an app that test vision, which has been used in over 100 countries since it was released last year. Non-health experts can use the app, and it can also be used in smaller spaces than traditional alphabet-based eye chart testing, which, Peek explains, means that more people can be reached and tested.

An element within Peek Acuity, PeekSim, has been created to show what a person with a vision problem really sees compared with normal vision just after they have had their vision tested.

By teaming-up with schools and communities in Kenya, Botswana and India, more than 100,000 children have had their eyes tested with Peek using the Peek School Screening programme and followed up for treatment or glasses where needed, and Peek is carrying out research to improve and expand these programmes.

Peek began as a result of Dr Bastawrouss experiences of transporting eye equipment to rural communities in Kenya to gather eye health data for his PhD at the London School of Hygiene & Tropical Medicine.

At the launch event the ophthalmologist and assistant professor in International Eye Health at the London school, Dr Bastawrous, said: We are extremely grateful to everyone who has supported us and helped us take ideas from research to reality and we will continue to learn and develop the tools and knowledge which healthcare providers and systems need to help those with avoidable sight loss.

While large numbers of people remain unable to see or access eye care, our job remains unfinished.

Peek Retina is available via the website and costs 216 (including VAT) plus delivery charge. The Peek Acuity and Peek Acuity Pro apps can be downloaded for free via the Google Play store.

To support Peek, visit the JustGiving pageor contact enquiries@peekvision.org

Read more here:
New tool to combat avoidable blindness - AOP

Read More...

Page 1,021«..1020..1,0201,0211,0221,023..1,0301,040..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick